Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Genomictree Inc. specializes in advanced genomic diagnostics, particularly in cancer detection and personalized medicine. The company leverages proprietary technologies and a vast database of genomic information to provide precise and timely diagnostic solutions, primarily in South Korea and expanding into other Asian markets.
Genomictree generates revenue primarily through genomic testing services, which are priced based on the complexity and urgency of the tests. The company has a competitive edge due to its proprietary algorithms that enhance diagnostic accuracy, and it benefits from strong partnerships with hospitals and research institutions.
Regulatory approvals for new diagnostic tests
Partnership announcements with healthcare providers
Advancements in genomic research and technology
Market expansion into new geographies
Technological disruption from emerging diagnostic technologies
Regulatory changes affecting testing protocols and approvals
Increased competition from established players in the genomic space
Potential market entry by new biotech firms with innovative solutions
Negative cash flow impacting liquidity and operational flexibility
High reliance on continued investment in R&D without immediate returns
moderate - The demand for genomic testing is somewhat insulated from economic cycles, but broader healthcare spending can be affected by GDP growth.
Interest rates impact Genomictree's cost of capital for funding R&D initiatives. Higher rates could increase financing costs, potentially affecting growth investments.
minimal - The company operates with no debt, reducing its exposure to credit market fluctuations.
growth - Investors are likely attracted to Genomictree for its potential in the rapidly expanding field of personalized medicine.
high - The stock has shown significant price fluctuations, evidenced by a 57% decline over the past six months.